Advertisement

Journal of Endocrinological Investigation

, Volume 28, Issue 2, pp 1003–1008 | Cite as

The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome

  • M. YilmazEmail author
  • A. Biri
  • A. Karakoç
  • F. Törüner
  • B. Bingöl
  • N. Çakir
  • B. Tiras
  • G. Ayvaz
  • M. Arslan
Original Article

Abstract

Aim: The aim of this study was to assess the effects of metformin and rosiglitazone on insulin resistance and serum androgen levelsin both obese and lean patients with polycystic ovary syndrome (PCOS). Materials and methods: Forty lean [body mass index (BMI) <25 kg/m2] and 40 overweight and obese (BMI>²5 kg/m2) patients were included in the study. Waist and hip measurements, serum sex steroid levels, insulin response to 75-g oral glucose tolerance test, fasting insulin, fasting C-peptide levels and homeostasis modelassessment of insulin resistance (HOMA-IR) were determined in all patients. The degree of hirsutism was determined by the Ferriman-Gallwey scoring system. Patients were divided into two groups, with 40 (20 overweight and obese; 20 non-obese) patients each. One group was treated with metformin (MET group) 850 mg bid while the other received rosiglitazone (ROSI group) 4 mg/day for 12 weeks. All measurements were repeated at the end of this period. Results: After the 12-week treatment period, HOMA-IR, area under the curve of insulin, fasting insulin and C-peptide levels were observed to have be decreased significantly in all groups. The decrease in the parameters mentioned above was similar in the four groups. The serum levels of free testosterone, androstenedione and DHEA-S decreased in all groups, but the decrease was statistically significant only in the ROSI groups. Within the lean MET group one patient became pregnant and was hence excluded from the final data analysis. Menstruations became regular after metformin therapy in 41.6% of lean and 35.7% of obese patients who had menstrual disturbance prior to the study. Rosiglitazone therapy improved menstrual disturbance in 61.5 % of lean and 53.8% of obese patients. Conclusions: Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well. Rosiglitazone seemed to be more effective in decreasing the androgen levels and in achieving slightly greater improvement in menstrual disturbance than metformin.

Key-words

Androgen insulin resistance metformin PCOS rosiglitazone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frank S. Polycystic ovary syndrome. N Engl J Med 1995, 333: 853–61.CrossRefGoogle Scholar
  2. 2.
    Homburg R. What is polycystic ovarian syndrome? Human Reprod 2003, 17: 2495–9.CrossRefGoogle Scholar
  3. 3.
    Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38: 1165–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18: 774–800.PubMedGoogle Scholar
  5. 5.
    Ehrman DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22: 141–6.CrossRefGoogle Scholar
  6. 6.
    Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association. Endocr Rev 2003, 24: 302–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000, 52: 595–600.CrossRefGoogle Scholar
  8. 8.
    Bailey CJ, Turner RC. Metformin. N Engl J Med 1996, 334: 574–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43: 647–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance andhyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998, 138: 269–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999, 51: 231–6.CrossRefGoogle Scholar
  12. 12.
    Kolodziecjzyk B, Dubela AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenizm and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000, 73: 1149–54.CrossRefGoogle Scholar
  13. 13.
    Vandermolen DT, Patts VS, Evans WS. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001, 75: 310–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double- blinded placebo-controlled trial. Hum Reprod 2001, 1625–31.Google Scholar
  15. 15.
    Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 524–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Crave JC, Fimbel S, Lejeune H N, Cugnardey H, Dechaud M. Effects of diet and metformin administration on sex-hormone binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80: 2057–62.PubMedGoogle Scholar
  17. 17.
    Acbay O, Gundogan S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996, 65: 946–9.PubMedGoogle Scholar
  18. 18.
    Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82: 524–30.PubMedGoogle Scholar
  19. 19.
    Goldstein BJ. Current views on the mechanisms of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther 1999, 1: 267–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Belli S, Graffigma M, Oneto A, Otero P, Schurman L, Levalle O. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004, 81: 624–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003, 10: 99–104.PubMedCrossRefGoogle Scholar
  22. 22.
    Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance J Clin Endocrinol Metab 2005, 90: 60–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Cataldo N, Abassi F, Mc Laughlin T, Lamendola C, Reaven G. Improvement in insulin sensivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001, 75: 1057–9.CrossRefGoogle Scholar
  24. 24.
    Ghazeeri G, Kutteh WH, Bryer-Arsh M, Haas D, Ke EW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003, 79: 562–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Bulgan Kilicdag E, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2004, 23: 894–9.CrossRefGoogle Scholar
  26. 26.
    Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004, 82: 893–902.PubMedCrossRefGoogle Scholar
  27. 27.
    The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19: 41–7.CrossRefGoogle Scholar
  28. 28.
    Ferriman D, Gallwey JD. Clinical assesment of body hair growth in women J Clin Endocrinol Metab 1961, 21: 1440–7.PubMedCrossRefGoogle Scholar
  29. 29.
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26: 3160–7.CrossRefGoogle Scholar
  30. 30.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Cara JF, Fan J, Azzarello J. Insulin-like growth factor I enhances luteinizing hormone binding to rat ovarian thecaintersitisal cells. J Clin Invest 1990, 86: 560–5.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with polycystic ovary syndrone. J Clin Endocrinol Metabol 1991, 72: 83–9.CrossRefGoogle Scholar
  33. 33.
    Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17alfa activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335: 617–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Kelestimur F, Sahin Y. Alternate pathway 17,20-lyase enzyme activitiy in the adrenals is enhanced in patients with polycystic ovary syndrome. Fertil Steril 1999, 71: 1075–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Frank S, Gilling-Smith C, Watson H. Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999, 28: 361–78.CrossRefGoogle Scholar
  36. 36.
    Maciel GAR, Junior JMS, Da Motta ELA, et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004, 81: 355–60.PubMedCrossRefGoogle Scholar
  37. 37.
    De Leo V, Marca A, Petraglia F. Insulin lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003, 24: 633–67.PubMedCrossRefGoogle Scholar
  38. 38.
    Azziz R, Ehrman D, Legro RS, Fereshetian AG, O’Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in woman with polycystic ovary syndrome. Fertil Steril 2003, 79: 932–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 2001, 276: 16767–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Marca A, Egbe TO, Morgante G, et al. Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000, 15: 21–3.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2005

Authors and Affiliations

  • M. Yilmaz
    • 1
    Email author
  • A. Biri
    • 2
  • A. Karakoç
    • 3
  • F. Törüner
    • 3
  • B. Bingöl
    • 2
  • N. Çakir
    • 3
  • B. Tiras
    • 2
  • G. Ayvaz
    • 3
  • M. Arslan
    • 3
  1. 1.Endocrinology and MetabolismKýrýkkale University Faculty of MedicineKirikkaleTurkey
  2. 2.Obstetrics and GynecologyGazi University Faculty of MedicineAnkaraTurkey
  3. 3.Endocrinology and MetabolismGazi University Faculty of MedicineAnkaraTurkey

Personalised recommendations